Metastatic Pancreatic Cancer - Pipeline Review, H1 2012

Metastatic Pancreatic Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Metastatic Pancreatic Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Pancreatic Cancer Therapeutic Products under Development, Key Players in Metastatic Pancreatic Cancer Therapeutics, Metastatic Pancreatic Cancer Pipeline Overview, Metastatic Pancreatic Cancer Pipeline, Metastatic Pancreatic Cancer Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Pancreatic Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer Therapeutics under Development by Companies
Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Pancreatic Cancer Therapeutics – Products under Development by Companies
Metastatic Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Eli Lilly and Company
Infinity Pharmaceuticals, Inc.
FibroGen, Inc.
Astellas Pharma Inc.
Chugai Pharmaceutical Co. Ltd
Pfizer Inc.
Celgene Corporation
Bayer AG
IMMUNOMEDICS, INC
Oncolytics Biotech Inc.
NanoCarrier Co., Ltd.
Rexahn Pharmaceuticals, Inc.
Oncoscience AG
MacroGenics, Inc.
OncoMed Pharmaceuticals, Inc.
Immutep S.A.
AB Science
Clovis Oncology, Inc.
Theradex Systems, Inc.
Metastatic Pancreatic Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG-479 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-4126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-C225 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Dalteparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 479 + Gemzar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abraxane + Gemzar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB1010 + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib Hydrochloride + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Capecitabine + Telovac + GM-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Pancreatic Cancer Therapeutics – Drug Profile Updates
Metastatic Pancreatic Cancer Therapeutics – Discontinued Products
Metastatic Pancreatic Cancer Therapeutics - Dormant Products
Metastatic Pancreatic Cancer – Product Development Milestones
Featured News & Press Releases
Jan 09, 2012: Clovis Oncology Announces Pivotal Trial Results Of CO-101
Jul 20, 2011: NanoCarrier Commences Phase II Study Of Nanoplatin
Jun 08, 2011: PharmaMar Commences Phase II Trials With PM01183 In Metastatic Pancreatic Cancer
May 19, 2011: Infinity Announces Clinical Data Of IPI-926 To Be Presented At ASCO
Mar 23, 2011: Tragara To Present Apricoxib Posters At 2011 AACR 102nd Annual Meeting
Jan 21, 2011: FibroGen Reports Interim Results Of Phase I/II Trial Of FG-3019 In Metastatic Pancreatic Cancer
Sep 02, 2010: Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Agensys
Jul 20, 2010: Seattle Genetics And Agensys Initiate Phase I Clinical Trial Of ASG-5ME For Metastatic Pancreatic Cancer
Jun 07, 2010: Clivatuzumab Tetraxetan Shows Promising Results In Patients With Metastatic Pancreatic Cancer
Jun 07, 2010: Immunomedics Reports Updated Results Of Targeted Therapy For Advanced Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Pancreatic Cancer, H1 2012
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
F. Hoffmann-La Roche Ltd., H1 2012
Amgen Inc., H1 2012
Eli Lilly and Company, H1 2012
Infinity Pharmaceuticals, Inc., H1 2012
FibroGen, Inc., H1 2012
Astellas Pharma Inc., H1 2012
Chugai Pharmaceutical Co. Ltd, H1 2012
Pfizer Inc., H1 2012
Celgene Corporation, H1 2012
Bayer AG, H1 2012
IMMUNOMEDICS, INC, H1 2012
Oncolytics Biotech Inc., H1 2012
NanoCarrier Co., Ltd., H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
Oncoscience AG, H1 2012
MacroGenics, Inc., H1 2012
OncoMed Pharmaceuticals, Inc., H1 2012
Immutep S.A., H1 2012
AB Science, H1 2012
Clovis Oncology, Inc., H1 2012
Theradex Systems, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Metastatic Pancreatic Cancer Therapeutics – Drug Profile Updates
Metastatic Pancreatic Cancer Therapeutics – Discontinued Products
Metastatic Pancreatic Cancer Therapeutics – Dormant Products
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..1)
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..2)
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..3)
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..4)
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..5)

List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2012
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012